Immunocore
IMCR
115 hedge funds and large institutions have $1.34B invested in Immunocore in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 44 reducing their positions, and 27 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
44% more call options, than puts
Call options by funds: $1.76M | Put options by funds: $1.22M
0.21% more ownership
Funds ownership: 90.56% → 90.77% (+0.21%)
5% less capital invested
Capital invested by funds: $1.41B → $1.34B (-$71M)
12% less funds holding
Funds holding: 130 → 115 (-15)
16% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 44
52% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$38.7M |
| 2 |
Citigroup
New York
|
+$19.5M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$16.4M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$14.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$19M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.7M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$12.3M |
| 4 |
Morgan Stanley
New York
|
-$8.67M |
| 5 |
BNP Paribas Asset Management
Paris,
France
|
-$8.41M |
IMCR Hedge Fund Activity: Q4 2024 in Review
115 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q4 2024, worth a combined $1.34B — down 5% from $1.41B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of IMCR and 13 opened new positions — a net loss of 14 holders — while 44 trimmed existing stakes and 37 added.
The largest buyer was Kynam Capital Management, opening a new position worth an estimated $38.7M. The largest seller was BlackRock, cutting an estimated $19M.
- 115 institutional investors held Immunocore (IMCR) as of Q4 2024, down from 130 in Q3 2024.
- Funds reported $1.34B of Immunocore stock for Q4 2024, down 5% quarter-over-quarter.
- 13 funds opened new Immunocore positions in Q4 2024 and 27 closed out, a net change of -14 holders.
- The largest Immunocore buyer in Q4 2024 was Kynam Capital Management, an estimated $38.7M added.
- The largest Immunocore seller in Q4 2024 was BlackRock, an estimated $19M sold.
Based on aggregated 13F filings for Q4 2024.